BIO Alabama

Incredible event!

We are thrilled to receive a New Grant from Southern Research, Station 41, and Innovate Alabama to support the final safety studies of our eczema patch, prior to beginning clinical trials later this year. We are on a mission to change the treatment paradigm for the > 20M patients suffering from localized eczema and psoriasis with our safer, easier patch treatment system. https://lnkd.in/eCXQjuUE

What a great night! I can't wait to see the the seeds planted there grow into new collaborations and innovations that strengthen our biotech sector here in South Alabama.

Our executive director, Kathy Nugent, Ph.D., has been named Senior Associate Vice President and Chief Biotechnology and Innovation Officer for the University of Alabama at Birmingham. Congratulations to an incredible leader!

We had such an exciting and inspiring gathering last week at the Grand Hotel in Point Clear showcasing South Alabama’s thriving BioTech ecosystem with groundbreaking innovations shaping the future of technology, healthcare, and agriculture. The room was filled with passionate individuals connecting and sharing ideas making progress in the fields of bioscience, biotechnology and innovation. Thank you Hatch Fairhope and to our amazing partners—Coastal Alabama Community College, City Of Fairhope, Baldwin County Economic Development Alliance and Innovate Alabama. Also, a special thanks to our sponsors C2 Wealth Strategies and Collaborative Drug Discovery - CDD Vault for their generous support in making this event possible. #BIOAlabama #HatchFairhope #CACC #CityofFairhope #BaldwinCountyEconomicDevelopmentAlliance #InnovateAlabama #C2WealthStrategies #CollaborativeDrugDiscovery #CDDVault #GrandHotelPointClear #Bioscience #Biotech #bioinnovation

Did you know that Dothan is known as the Peanut Capital of the World? The heart of the Wiregrass thrives because of the hardworking communities that sustain it. Within a 100-mile radius, you'll find the majority of the peanuts grown in the United States—feeding industries, supporting local economies, and carrying on a rich agricultural legacy. From dedicated farmers to innovative researchers, we’re not just growing peanuts—we’re growing opportunities, strengthening communities, and inspiring the next generation of agricultural leaders! ???? Happy National Peanut Month! ????#NationalPeanutMonth #HudsonAlphaWiregrass #DiscoveringWiregrassDNA

In business news, ?IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies, today unveiled INB-600, its potentially breakthrough next generation γδ T cell-based TCE platform. It is designed to address one of the biggest shortcomings of current existing γδ TCEs – insufficient numbers of γδ T cell effector cells to drive real clinical impact. This groundbreaking platform leverages γδ T cells’ unique properties targeting applications in both oncology and autoimmune indications with potentially greater safety and tolerability than current CAR-T and TCE approaches. The platform’s first candidate, INB-619, targets CD19, a key marker broadly found on B cells, which play a central role in leukemias, lymphomas, and autoimmune diseases. IN8bio plans to evaluate INB-619 in preclinical studies and seek potential partners to support future IND-enabling trials. #mabs https://lnkd.in/eMyhzzKB

Yesterday we presented at the TD Cowen 45th Healthcare Conference. Excited to introduce our latest innovation—the INB-600 platform! Why does this matter? ? T cell engagers (TCEs) have been one of the biggest success stories in immunotherapy, with companies like J&J and Roche building billion-dollar franchises around these therapies. ? Despite the promise, gamma-delta T cell engagers have struggled—until now. ? Our INB-619 preclinical candidate is designed to not only engage γδ T cells but also expand them, creating a more powerful, longer-lasting immune response for blood cancers and autoimmune diseases. ? Unlike traditional CD3-based TCEs, which come with severe risks like cytokine release syndrome and neurotoxicity, our approach could offer a safer, more effective alternative. This is a game-changing moment for gamma-delta T cell therapies. Stay tuned for more updates as we continue to work on achieving our goal of #CancerZero!? #Biotech #Immunotherapy #CancerResearch #TcellEngagers #GDTcells

#NEWS: We are pleased to announce new data on our next-generation gamma-delta (γδ) T cell Engager (TCE) platform for oncology and autoimmune diseases – INB-600. INB-600 is a novel γδ T cell-based TCE platform designed to address one of the biggest shortcomings of current existing γδ TCEs – insufficient numbers of γδ T cell effector cells to drive real clinical impact. This technology is designed to efficiently eliminate target cells while stimulating γδ T cell expansion to drive deeper and potentially longer-lasting immune responses. By leveraging our expertise in γδ T cell biology, we have developed a technology that combines exceptional preclinical potency while broadly expanding immune surveillance and potentially avoiding the dangerous side effects of existing approaches. Our CEO, William Ho, will discuss this platform and data today at 10:30 a.m. EST at the TD Cowen 45th Annual Health Care Conference. A webcast will also be available. Read more: bit.ly/3EW6oFB

INAB: IN8bio Continued Survival in INB-100 Trial https://buff.ly/4i1bbnu #smallcaps #biotech